Assertio Therapeutics Stock Performance
| ASRT Stock | USD 0.84 0.02 2.33% |
Assertio Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.0825, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Assertio Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Assertio Therapeutics is expected to be smaller as well. Assertio Therapeutics right now shows a risk of 3.44%. Please confirm Assertio Therapeutics value at risk, as well as the relationship between the kurtosis and market facilitation index , to decide if Assertio Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Assertio Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Assertio Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Last Split Factor 1:4 | Last Split Date 2021-05-18 |
1 | Acquisition by Heather Mason of 75000 shares of Assertio Therapeutics at 0.8 subject to Rule 16b-3 | 11/18/2024 |
2 | Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer | 12/06/2024 |
3 | Assertio Announces Results of Rolvedon injection Same-Day Dosing Clinical Study | 12/13/2024 |
4 | Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors | 12/17/2024 |
5 | Insider Trading | 01/02/2025 |
6 | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635 | 01/03/2025 |
7 | Acquisition by Heather Mason of 25000 shares of Assertio Therapeutics at 0.97 subject to Rule 16b-3 | 01/10/2025 |
8 | Disposition of 19404 shares by Sam Schlessinger of Assertio Therapeutics subject to Rule 16b-3 | 01/21/2025 |
9 | Acquisition by Staple Peter D of 53750 shares of Assertio Therapeutics subject to Rule 16b-3 | 02/06/2025 |
10 | Disposition of 25000 shares by Ajay Patel of Assertio Therapeutics subject to Rule 16b-3 | 02/07/2025 |
11 | Carestream Makes Contribution to Scholarship Program with New Corporate Partner American Society of Radiologic Technologists | 02/10/2025 |
12 | Assertio Investor Deadline Approaching - Newsfile | 02/13/2025 |
| Begin Period Cash Flow | 64.9 M |
Assertio |
Assertio Therapeutics Relative Risk vs. Return Landscape
If you would invest 84.00 in Assertio Therapeutics on November 18, 2024 and sell it today you would earn a total of 0.00 from holding Assertio Therapeutics or generate 0.0% return on investment over 90 days. Assertio Therapeutics is currently generating 0.0564% in daily expected returns and assumes 3.4411% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Assertio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Assertio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Assertio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Assertio Therapeutics, and traders can use it to determine the average amount a Assertio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0164
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ASRT | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.44 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Assertio Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Assertio Therapeutics by adding it to a well-diversified portfolio.
Assertio Therapeutics Fundamentals Growth
Assertio Stock prices reflect investors' perceptions of the future prospects and financial health of Assertio Therapeutics, and Assertio Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Assertio Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.0144 | ||||
| Profit Margin | (0.54) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 31.49 M | ||||
| Shares Outstanding | 95.34 M | ||||
| Price To Earning | 4.93 X | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 0.64 X | ||||
| Revenue | 152.07 M | ||||
| Gross Profit | 138.29 M | ||||
| EBITDA | (222.45 M) | ||||
| Net Income | (331.94 M) | ||||
| Cash And Equivalents | 52.26 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 40.91 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 1.00 X | ||||
| Book Value Per Share | 1.38 X | ||||
| Cash Flow From Operations | 49.6 M | ||||
| Earnings Per Share | (4.94) X | ||||
| Market Capitalization | 81.8 M | ||||
| Total Asset | 286.42 M | ||||
| Retained Earnings | (651.54 M) | ||||
| Working Capital | 77.62 M | ||||
| Current Asset | 5.15 M | ||||
| Current Liabilities | 492.4 K | ||||
About Assertio Therapeutics Performance
Assessing Assertio Therapeutics' fundamental ratios provides investors with valuable insights into Assertio Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Assertio Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 585.44 | 315.88 | |
| Return On Tangible Assets | (1.71) | (1.62) | |
| Return On Capital Employed | (1.14) | (1.08) | |
| Return On Assets | (1.04) | (0.99) | |
| Return On Equity | (2.77) | (2.63) |
Things to note about Assertio Therapeutics performance evaluation
Checking the ongoing alerts about Assertio Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Assertio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Assertio Therapeutics has some characteristics of a very speculative penny stock | |
| Assertio Therapeutics had very high historical volatility over the last 90 days | |
| Assertio Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 152.07 M. Net Loss for the year was (331.94 M) with profit before overhead, payroll, taxes, and interest of 138.29 M. | |
| Latest headline from news.google.com: Assertio Investor Deadline Approaching - Newsfile |
- Analyzing Assertio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Assertio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Assertio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Assertio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Assertio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Assertio Therapeutics' stock. These opinions can provide insight into Assertio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.